Vanguard Global Advisers
AGIO icon

Vanguard Global Advisers’s Agios Pharmaceuticals AGIO Stock Holding History

Vanguard Global Advisers’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$865K Sell
23,317
-35
-0.1% -$1.06K ﹤0.01% 1827
2026
Q1 		$790K Buy
+23,352
New +$662K ﹤0.01% 1781

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Vanguard Global Advisers's AGIO Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Agios Pharmaceuticals (AGIO) stake by 0.15% in Q2 2026, selling an estimated $1.06K and leaving 23,317 shares worth $865K. The position accounts for ﹤0.01% of the portfolio, ranked #1827.

Vanguard Global Advisers first reported a position in AGIO in Q1 2026 and has held it in 2 quarters since. 236 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Vanguard Global Advisers held 23,317 shares of Agios Pharmaceuticals worth $865K as of Q2 2026.
  • Vanguard Global Advisers sold 35 Agios Pharmaceuticals shares in Q2 2026, an estimated $1.06K.
  • Agios Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1827 holding.
  • Vanguard Global Advisers first reported a position in Agios Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 236 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.